PMEL Recombinant Antibody

$Paraformaldehyde-fixed, paraffin embedded Human melanoma; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with PMEL Monoclonal Antibody, Unconjugated(bsm-61122R) at 1:200 overnight at 4\u00b0C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining$

Paraformaldehyde-fixed, paraffin embedded Human melanoma; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with PMEL Monoclonal Antibody, Unconjugated(bsm-61122R) at 1:200 overnight at 4\u00b0C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining

$25 ug total protein per lane of various lysates (see on figure) probed with PMEL monoclonal antibody, unconjugated (bsm-61122R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.$

25 ug total protein per lane of various lysates (see on figure) probed with PMEL monoclonal antibody, unconjugated (bsm-61122R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.

Applications

WB
IHC-P
IHC-F
IF(IHC-P)

Reactivity

Human

Overview
Catalog #	bsm-61122r
Product Name	PMEL Recombinant Antibody
Applications	WB IHC-P IHC-F IF(IHC-P)
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from human PMEL
Clonality	Recombinant
Isotype	IgG
Concentration	1mg/ml
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol
Storage Condition	Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	6490
Swiss Prot	P40967
Subcellular location	Extracellular, Secreted
Synonyms	PMEL; ME20-M; Premelanosome protein; Silver locus protein homolog; PMEL17; SILV.
Background	Plays a central role in the biogenesis of melanosomes. Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity.
Application Dilution
WB	1:500-2000
IHC-P	IHC-P1:100-500
IHC-F	IHC-F1:100-500
IF(IHC-P)	IFIHC-P1:100-500